You are here

A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer

Last updated on March 14, 2019

Study Location
Eligibility criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms, Neoplasm Metastasis
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Signed written and voluntary informed consent

- Histologically or cytologically confirmed breast cancer

- Stage IV (metastatic) breast cancer

- Biopsy (fresh or archival) of primary breast cancer or metastatic site demonstrating
HER2 gene amplification as determined in study-specified central laboratory by
fluorescence in situ hybridization (FISH)

- Prior treatment and progressive disease with at least 1 but not more than 2 cytotoxic
chemotherapy regimen(s) for metastatic disease

- Those for whom the use of an investigational HER2 inhibitor is appropriate because
they do not have access to approved HER2 inhibitors (e.g., Herceptin®) or for whom
treatment with currently available HER2 inhibitors is inappropriate

- Limited visceral disease burden (i.e., disease-related symptoms (i.e., well controlled with supportive care measures)

- Presence of at least one measurable target lesion [i.e., malignant tumor mass that can
be accurately measured in at least 1 dimension of >=2 cm with conventional
radiographic techniques or magnetic resonance imaging, or >=1 cm with spiral CT scan
as per RECIST], excluding previously irradiated lesions, bone metastasis or pleural
effusion as sole manifestations of disease. If the measurable disease is restricted to
a solitary lesion, its neoplastic nature must be confirmed by cytology/histology

- Eastern Cooperative Oncology Group (ECOG) performance status 0 1

- Patient available for treatment, monitoring, and follow-up. Willing and able to comply
with scheduled visits, therapy plan, laboratory tests and blood sampling for
pharmacokinetic (PK) analyses

- Recovery to baseline or NCI CTCAE Version 3.0 Grade 1 toxicity from all acute effects
related to prior treatment, except alopecia

- Adequate Bone Marrow Function, including: a. Absolute neutrophil count (ANC) >=1500
cells/mm3; b. Platelets >=100,000 cells/mm3

- Adequate Renal Function, including: a. Estimated creatinine clearance >=60 mL/min; b.

- Adequate Liver Function, including: a. Bilirubin (SGOT)

- Adequate Cardiac Function, including: a. 12-Lead electrocardiogram (ECG) with normal
tracing or non clinically significant changes that do not require medical
intervention; b. QTc interval or other symptomatic QTc abnormality; c. Left ventricular ejection fraction (LVEF) >=
institutional lower limit of normal and 45% as measured by echocardiogram or multi
gated radionuclide angiography (MUGA) within 4 weeks prior to start of study treatment

- >= 18 years old

- Female

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Women of child-bearing potential who are unwilling or unable to use an acceptable
method to avoid pregnancy for the entire study period and up to 4 weeks after study

- Women who are pregnant or breastfeeding

- Women with a positive pregnancy test on enrollment or within 72 hours prior to study
drug administration

- Prior treatment with trastuzumab (Herceptin®) or other HER2-targeting agents [e.g.,
lapatinib (GW572016), pertuzumab (Omnitarg?; rhuMab 2C4), CI 1033, EKB 569, CP

- Cumulative dose >450 mg/m2 of doxorubicin or doxorubicin equivalents

- Prior high-dose chemotherapy requiring hematopoetic stem cell transplantation within
12 months of study treatment start

- Radiotherapy, investigational chemotherapy, biologic therapy within 4 weeks of study
treatment start

- Previous (within the last 5 years) or current malignancies arising from sites other
than breast, except for adequately treated basal cell or squamous cell skin cancer or
in situ carcinoma of the cervix uteri

- Known or clinically suspected brain metastasis or leptomeningeal disease (no screening
CT scan required) requiring therapy. Patients with asymptomatic previously treated CNS
metastases that no longer require therapy or corticosteroids/anticonvulsants for at
least 4 weeks prior to start of study treatment are eligible

- Any clinically significant gastrointestinal abnormalities, which may impair intake,
transit or absorption of the study drug, such as the inability to take oral medication
in tablet form, prior complete/partial gastrectomy or intestinal resection, or a
requirement for H2 antagonists or proton pump inhibitors

- Any mental disorder that would limit the understanding or rendering of informed
consent and/or compromise compliance with the requirements of this protocol

- Uncontrolled or significant cardiovascular disease, including: a. Myocardial
infarction within 12 months; b. Uncontrolled angina within 6 months; c. Congestive
heart failure within 6 months or left ventricular ejection fraction below local
institutional lower limit of normal or below 45%; d. Diagnosed or suspected congenital
long QT syndrome; e. Any history of clinically significant ventricular arrhythmias
(such as ventricular tachycardia, ventricular fibrillation, or torsade de pointes); f.
Prolonged QTc interval on pre-entry electrocardiogram (>450 msec); g. Any history of
second or third degree heart block (may be eligible if currently have a pacemaker); h.
Heart rate

- History of drug-induced hyperbilirubinemia

- Concurrent treatment with approved or investigational chemotherapy, hormonal therapy,
immunotherapy, or radiotherapy (hormone replacement therapy is permitted)

- Concurrent treatment with H2 antagonists and/or proton pump inhibitors. However, H2
antagonists can be used for the treatment of an unexpected hypersensitivity reaction
during the study period. Antacids are allowed but only up to 2 hours before and 2
hours after study drug administration

- Concurrent treatment or treatment within 4 weeks of first dose with potent and/or
irreversible CYP3A4 inhibitors including: ketoconazole, itraconazole, troleandomycin,
clarithromycin, erythromycin, ritonavir, indinavir, nelfinavir, saquinavir,
nefazodone, mibefradil, amiodarone and grapefruit juice

- Concurrent treatment or treatment within 4 weeks of first dose with potent inducers of
CYP3A4 including: rifampin, rifabutin, rifamycins, phenytoin, barbiturates,
carbamazepine, glucocorticoids, modafinil, phenobarbital, troglitazone, pioglitazone,
efavirenz, nevirapine, dexamethasone, and St. John's wort

- Prisoners or patients who are compulsorily detained or involuntarily incarcerated
(e.g., for treatment of infectious disease, psychiatric illness, etc.)

A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center


[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Neoplasms, Breast Neoplasms
All Genders
Multiple Sites
Breast Neoplasms, Stomach Neoplasms, Esophagogastric Junction Neoplasm, Non-small-cell Lung Carcinoma
All Genders
Multiple Sites


Contact a representative by phone, email, or visiting the study website. Please see the references below:


Pfizer Clinical Trials Contact Center




[email protected]

Call Now